Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?

SIMPLE SUMMARY: Previous studies have shown that the use of chemotherapy in combination with immune checkpoint inhibitors as a first-line treatment in patients with non-small cell lung cancer improved overall survival and progression-free survival. However, the efficacy of cytotoxic agents as a seco...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Tadashi, Fujimoto, Hajime, Okano, Tomohito, Naito, Masahiro, Tsuji, Chikashi, Iwanaka, Soichi, Sakakura, Yasumasa, Yasuma, Taro, D’Alessandro-Gabazza, Corina N., Oomoto, Yasuhiro, Gabazza, Esteban C., Kobayashi, Tetsu, Ibata, Hidenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221111/
https://www.ncbi.nlm.nih.gov/pubmed/35740634
http://dx.doi.org/10.3390/cancers14122970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221111/
https://www.ncbi.nlm.nih.gov/pubmed/35740634
http://dx.doi.org/10.3390/cancers14122970

Ejemplares similares